Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P00325
UPID:
ADH1B_HUMAN
Alternative names:
Alcohol dehydrogenase 1B; Alcohol dehydrogenase subunit beta
Alternative UPACC:
P00325; A8MYN5; B4DRS9; B4DVC3; Q13711; Q4ZGI9; Q96KI7
Background:
All-trans-retinol dehydrogenase [NAD(+)] ADH1B, also known as Alcohol dehydrogenase 1B and Alcohol dehydrogenase subunit beta, plays a pivotal role in retinoid metabolism. It catalyzes the NAD-dependent oxidation of all-trans-retinol and its derivatives, contributing significantly to the biological processes involving vitamin A. The enzyme exhibits a preference for the oxidative direction, showcasing higher efficiency in this pathway.
Therapeutic significance:
Understanding the role of All-trans-retinol dehydrogenase [NAD(+)] ADH1B could open doors to potential therapeutic strategies. Its involvement in retinoid metabolism suggests its potential impact on conditions related to vitamin A deficiency or excess, offering a promising avenue for research into novel treatments.